License Agreements (Narrative) (Details) - USD ($)	1 Months Ended								12 Months Ended
	Oct. 25, 2016	Jun. 30, 2016	Nov. 19, 2013	Jul. 31, 2011	Apr. 30, 2011	Feb. 28, 2011	Jun. 30, 2009	Apr. 30, 2009	Dec. 31, 2017	Dec. 31, 2010	May 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 08, 2010
Additional consideration								$ 12,500
Minimum royalty payment for first three years, per year										$ 10,000						$ 10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									$ 20,000			$ 20,000	$ 20,000	$ 20,000	$ 20,000
Milestone payment									1,000		$ 500,000
Milestone payment upon annual net sales of $100,000,000 or more												250,000
Option fees																		$ 2,000
Exercise of stock options				$ 10,000
Maintenance fee	$ 82,000
Upfront fee	$ 20,000
Pelican Therapeutics, Inc. [Member]
Minimum royalty payment for first three years, per year										10,000						10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									$ 20,000			20,000	20,000	20,000	20,000
Percentage of all issued and outstanding stock to be issued with license agreement									2.50%
License agreement ("SS114A") [Member]
Reimbursement of for past patent fees						$ 37,381
License Agreement ("143") [Member]
Reimbursement of for past patent fees						50,000
License Agreement ("J110") [Member]
Reimbursement of for past patent fees						10,000
License Agreement for Multiple Myeloma [Member]
Maintenance fee									$ 5,000
License 0331, 0539 [Member] | Pelican Therapeutics, Inc. [Member]
Milestone payments due upon submission									150,000
Milestone payments completion of phase 1 clinical trial									250,000
License I176 [Member] | Pelican Therapeutics, Inc. [Member]
Minimum royalty payment for first three years, per year														$ 10,000	$ 10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									20,000			$ 20,000	$ 20,000
License Costs										50,000
Reimbursement of for past patent fees										$ 15,797
Milestone payments due upon submission									150,000
Milestone payments completion of phase 1 clinical trial									$ 500,000
UMM143 [Member] | Pelican Therapeutics, Inc. [Member]
License Costs			$ 35,000
Not For Profit Corporation Fee Two [Member]
License Costs					$ 50,000
Patents [Member] | License Agreement ("143") [Member]
License Costs						14,158
Patents [Member] | License Agreement ("J110") [Member]
License Costs						$ 1,055
SubsidiaryOneMember | Not For Profit Corporation Fee Two [Member]
Percentage of issued and outstanding stock owned							7.50%
Shattuck Labs, Inc. ("Shattuck") Member
License Costs		$ 50,000